UK-based ReViral Ltd has raised $55 million in a Series B financing round to advance a small molecule drug against respiratory syncytial virus (RSV) infection into a Phase 2a trial in children. The drug, RV521, has been successfully tested in a Phase2a challenge trial in healthy adults.
RSV is a pathogen that infects the human respiratory tract, potentially leading to bronchiolitis and pneumonia. While healthy adults usually recover from infection, the virus poses a risk to premature infants, the elderly and individuals with certain pulmonary conditions.